Pueraria lobate Inhibits RANKL-Mediated Osteoclastogenesis Via Downregulation of CREB/PGC1β/c-Fos/NFATc1 Signaling

被引:34
|
作者
Park, Keun Ha [1 ]
Gu, Dong Ryun [1 ,2 ]
Jin, Su Hyun [2 ]
Yoon, Chi-Su [3 ,4 ]
Ko, Wonmin [3 ,4 ]
Kim, Youn Chul [3 ,4 ]
Lee, Seoung Hoon [1 ,2 ,5 ]
机构
[1] Wonkwang Univ, Coll Dent, Dept Oral Microbiol & Immunol, 460 Iksandae Ro, Iksan 54538, Jeonbuk, South Korea
[2] Wonkwang Univ, CMFR, Sch Med, Iksan 54538, Jeonbuk, South Korea
[3] Wonkwang Univ, Inst Pharmaceut Res & Dev, Coll Pharm, Iksan 54538, Jeonbuk, South Korea
[4] Wonkwang Univ, Standardized Mat Bank New Bot Drugs, Coll Pharm, Iksan 54538, Jeonbuk, South Korea
[5] Wonkwang Univ, Inst Biomat & Implant, Iksan 54538, Jeonbuk, South Korea
来源
AMERICAN JOURNAL OF CHINESE MEDICINE | 2017年 / 45卷 / 08期
关键词
Pueraria lobate; Puerariae radix; Osteoclast; NFATc1; PGC1; beta; CREB; Bone Disease; PREVENTS BONE LOSS; HORMONE REPLACEMENT THERAPY; RANDOMIZED CONTROLLED-TRIALS; OVARIECTOMIZED MICE; MINERAL DENSITY; POSTMENOPAUSAL WOMEN; RECEPTOR ACTIVATOR; SOY ISOFLAVONES; IN-VITRO; PHYTOESTROGENS;
D O I
10.1142/S0192415X17500938
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Puerariae radix, the dried root of Pueraria lobate Ohwi, is known to prevent bone loss in ovariectomized mice; however, the precise molecular mechanisms are not understood. In this study, we investigated the effects and underlying mechanisms of action of Puerariae radix extract (PRE) on receptor activator of NF-kappa B ligand (RANKL)-induced osteoclastogenesis. PRE dose-dependently inhibited osteoclast differentiation and formation, decreased the bone-resorbing activity of osteoclasts, and downregulated the expression of osteoclast differentiation marker genes. The expression of osteoclastogenic factors produced by PRE-treated osteoblasts such as RANKL, macrophage colony-stimulating factor (M-CSF), and osteoprotegerin (OPG) was comparable to that of untreated (control) cells. However, the formation of osteoclasts via bone marrow cell and calvaria-derived osteoblast co-cultures was suppressed by PRE treatment. Therefore, the inhibitory effects of PRE on osteoclastogenesis clearly targeted osteoclasts, but not osteoblasts. PRE treatment considerably reduced RANKL-induced mitogen-activated protein kinases (MAPKs) activity, especially c-Jun N-terminal kinase, in osteoclast precursor cells. In addition, PRE markedly suppressed cAMP response element-binding protein (CREB) activation and the induction of peroxisome proliferator-activated receptor gamma coactivator 1 beta (PGC1 beta), which stimulate osteoclastogenesis - an effect that was not observed for puerarin and 17-beta estradiol. Finally, PRE treatment significantly repressed the expression of c-Fos and the nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), which is a master transcription factor for osteoclastogenesis in vitro and in vivo. Overall, these results strongly suggest that PRE is an effective inhibitor of RANKL-induced osteoclastogenesis and may be a potent therapeutic agent for bone-related diseases such as osteoporosis, rheumatoid arthritis, and periodontitis.
引用
收藏
页码:1725 / 1744
页数:20
相关论文
共 50 条
  • [21] Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells
    Kong, Lingbo
    Zhao, Qinpeng
    Wang, Xiaodong
    Zhu, Jinyu
    Hao, Dingjun
    Yang, Chongfei
    BMC COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2014, 14
  • [22] Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB
    Kang, Jong Soon
    Kang, Moo Rim
    Jo, Sun Ah
    Han, Sang-Bae
    Kim, Youngsoo
    JOURNAL OF IMMUNOLOGY, 2015, 194
  • [23] Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells
    Lingbo Kong
    Qinpeng Zhao
    Xiaodong Wang
    Jinyu Zhu
    Dingjun Hao
    Chongfei Yang
    BMC Complementary and Alternative Medicine, 14
  • [24] Histone deacetylase inhibitor CI-994 inhibits osteoclastogenesis via suppressing NF-κB and the downstream c-Fos/NFATc1 signaling pathways
    Guo, Di
    Hong, Dun
    Wang, Peng
    Wang, Jiacheng
    Chen, Lihua
    Zhao, Weibo
    Zhang, Liwei
    Yao, Can
    Chu, Binxiang
    Chen, Shenao
    Li, Zhiyan
    Chen, Haixiao
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 848 : 96 - 104
  • [25] TACROLIMUS INHIBIT IL-1β AND ER STRESS-INDUCED, RANKL-MEDIATED OSTEOCLASTOGENESIS BY INHIBITING PERK, IRE1, GRP78, EIF2A, C-FOS AND NFATC1
    Lee, W. -S.
    Lee, E. -G.
    Sung, M. -S.
    Lee, C. -H.
    Lee, M. -S.
    Yoo, W. -H.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 838 - 838
  • [26] Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling
    Yang, Qin
    Guo, Jingyun
    Zheng, Jiehuang
    Chen, Yan
    Zou, Binhua
    Li, Ruopeng
    Ding, Zongbao
    Wang, Yiyuan
    Li, Lihong
    Chen, Ziye
    Mo, Lixia
    Liang, Qinghe
    Chen, Fengsheng
    Li, Xiaojuan
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 120
  • [27] Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway
    Huang, Hao
    Chang, Eun-Ju
    Ryu, Jiyoon
    Lee, Zang Hee
    Lee, Youngkyun
    Kim, Hong-Hee
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 351 (01) : 99 - 105
  • [28] Caffeic Acid Phenethyl Ester Inhibits Osteoclastogenesis through Suppression of NF-kappaB, NFATc1, and c-Fos
    Ha, J.
    Kim, H.
    MOLECULAR BIOLOGY OF THE CELL, 2006, 17
  • [29] IL-27 abrogates RANKL-mediated osteoclastogenesis through STAT1-dependent inhibition of c-Fos
    Yoshida, Hiroki
    Furukawa, Mitsuru
    Takaishi, Hironari
    CYTOKINE, 2009, 48 (1-2) : 97 - 97
  • [30] Inhibition of RANKL-induced osteoclast differentiation through the downregulation of c-Fos and NFATc1 by Eremochloa ophiuroides (centipedegrass) extract
    Choi, Bo-Yun
    Park, Chul-Hong
    Na, Yun Hee
    Bai, Hyoung-Woo
    Cho, Jae-Young
    Chung, Byung Yeoup
    MOLECULAR MEDICINE REPORTS, 2016, 13 (05) : 4014 - 4022